Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Related Haploidentical Donor and Unrelated Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China

Rongrong Liu, Gaohui Yang, Lingling Shi, Lianjin Liu, Zhongming Zhang, Cuifeng Huang, Zhenbin Wei, Beicai Liu, Zhaoping Gan, Wenqiang Xie, Rui Huang, Na Sun, Shuyi Wei, Xuemei Zhou, Yinghua Chen, Yanye Liu, Zhi Li, Qifa Liu, Yongrong Lai

Blood (2023) 142 (Supplement 1): 5252.

https://doi.org/10.1182/blood-2023-180056

Published: 2023

Journal Articles

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy with Dual Targeting of CD19 and CD70 to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Sanfang Tu, Lijuan Zhou, Rui Huang, Xuan Zhou, Jilong Yang, Meifang Li, Bo Jin, Langqi Wang, Yaqi Zhuo, Huifang Chen, Lung-Ji Chang, Yuhua Li

Blood (2023) 142 (Supplement 1): 3492.

https://doi.org/10.1182/blood-2023-186888

Published: 2023

Journal Articles

Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Trial

Chuting Yang, Yaling Zheng, Chaoyang Song, Ming Wu, Lei Wang, Xuan Zhou, Chunyan Yue, Xiaonan Lin, Jie Chen, Hui Zeng, Rui Huang, Yuhua Li

Blood (2023) 142 (Supplement 1): 7045.

https://doi.org/10.1182/blood-2023-174879

Published: 2023

Journal Articles

Venetoclax Combined with HMA Versus CAG Based Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis

Xiaonan Lin, Yuming Zhang, Ying Zhao, Ying Dong, Xiaotao Wang, Pengcheng Huang, Zhenqian Huang, Honghua He, Xiaoli Xu, Yaya Wang, Fang Jiang, Hui Zeng, Rui Huang, Yuhua Li

Blood (2023) 142 (Supplement 1): 2901.

https://doi.org/10.1182/blood-2023-182642

Published: 2023

Journal Articles

Dendritic Cell Vaccines Extend CD19 CAR-T Cell Persistence and Improve the Outcomes in Refractory/Relapsed Adult B-ALL

Sanfang Tu, Lijuan Zhou, Rui Huang, Yanjie He, Xuan Zhou, Jilong Yang, Yuxing Hu, Honghao Zhang, Lung-Ji Chang, Yuhua Li

Blood (2023) 142 (Supplement 1): 3488.

https://doi.org/10.1182/blood-2023-186308

Published: 2023

Journal Articles

Venetoclax Plus Azacitadine for Middle Aged and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial

Blood (2023) 142 (Supplement 1): 4263.

https://doi.org/10.1182/blood-2023-177568

Published: 2023

Journal Articles

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD22 to Treat Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults

Sanfang Tu, Lijuan Zhou, Rui Huang, Xuan Zhou, Jilong Yang, Meifang Li, Bo Jin, Langqi Wang, Yaqi Zhuo, Huifang Chen, Lung-Ji Chang, Yuhua Li

Blood (2023) 142 (Supplement 1): 6884.

https://doi.org/10.1182/blood-2023-186622

Published: 2023

Journal Articles

Linperlisib in Conjunction with Gemcitabine and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Multicenter, Single-Arm Phase Ib/II Study

Zhiming Li, Peng Sun, Hong Cen, Haiyan Yang, Rui Huang, Zhen Cai, Xuekui Gu

Blood (2023) 142 (Supplement 1): 1732.

https://doi.org/10.1182/blood-2023-178492

Published: 2023

Journal Articles

A Phase Ib Study of Linperlisib Monotherapy in Patients with Relapsed or Refractory B-Cell Malignancies

Wei Liu, Yunhong Huang, Haiyan Yang, Zhiming Li, Zhen Cai, Zhen Wang, Lihong Liu, Ye Guo, Ligen Liu, Rui Huang, Xu Ye, Lugui Qiu

Blood (2023) 142 (Supplement 1): 1722.

https://doi.org/10.1182/blood-2023-177550

Published: 2023

Journal Articles

Letermovir Prophylaxis for Cytomegalovirus Reactivation in β Thalassemia Major Children after Hematopoietic Cell Transplantation

Lingling Shi, Rongrong Liu, Zhongming Zhang, Cuifeng Huang, Lianjin Liu, Yibin Yao, Zhenbin Wei, Shuyi Wei, Zhaoping Gan, Na Sun, Beicai Liu, Rui Huang, Xuemei Zhou, Yinghua Chen, Qifa Liu, Yongrong Lai

Blood (2023) 142 (Supplement 1): 7053.

https://doi.org/10.1182/blood-2023-189043

Published: 2023

Journal Articles

Clinical Characteristics and Prognosis of Acute Myeloid Leukemia Patients with Protein Tyrosine Phosphatase Non-Receptor Type 11 Gene Mutation

Weihua Zhao, Rui Huang, Yiting Zhang, Yu Lin, Ruli Pang, Zhi Yang

Blood (2023) 142 (Supplement 1): 5863.

https://doi.org/10.1182/blood-2023-184840

Published: 2023

Journal Articles

Single-Arm Phase 1b/2 Trial of the PI3Kδ Inhibitor Linperlisib Combining with Gemox in Relapsed and/or Refractory Diffuse Large B Cell Lymphoma

Zhiming Li, Haiyan Yang, Hong Cen, Rui Huang, Zhen Cai, Xuekui Gu, Hanying Bao, Zusheng Xu, Zuhong Xu

Blood (2021) 138 (Supplement 1): 2483.

https://doi.org/10.1182/blood-2021-150041

Published: 2021

Journal Articles

Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Rui Zhang, MSc, Yuhua Li, MD& PhD, Sanfang Tu, MD& PhD, Rui Huang, MD& PhD, Xun Lai, MD, Leping Zhang, MD PhD, Eugene E. Zvonkov, MD PhD, Valeriy G. Savchenko, MD PhD, Nelly G Gabeeva, PhD, Yuchen Liu, MSc, Yuchen Li, MSc, Cheng Jiao, MD PhD, Lan Deng, MD PhD, Xuan Zhou, MD, Hongyu Zhang, MD PhD, Wenli Zhang, MD, Lung-Ji Chang, PhD

Blood (2020) 136 (Supplement 1): 47.

https://doi.org/10.1182/blood-2020-141515

Published: 2020

Journal Articles

A Novel Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD123 to Treat Relapsed Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Sanfang Tu, MD PhD, Lan Deng, MD PhD, Rui Huang, MD PhD, Xuan Zhou, MD, Jilong Yang, MD, Weijun Zhou, MD PhD, Meifang Li, MD PhD, Chunyan Yue, MD, Shaojie Wu, MD PhD, Zhenling Guo, Lung-Ji Chang, PhD, Yuhua Li, MD PhD

Blood (2018) 132 (Supplement 1): 4015.

https://doi.org/10.1182/blood-2018-99-118526

Published: 2018

Journal Articles

Therapy of 4s Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival with No Severe CRS or Cres in Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia

Sanfang Tu, MD PhD, Rui Huang, MD PhD, Lan Deng, MD PhD, Xuan Zhou, MD, Yanjie He, MD PhD, Weijun Zhou, MD PhD, Jilong Yang, MD, Chunyan Yue, MD, Anqin Wu, Meifang Li, MD PhD, Zhenling Guo, Lung-Ji Chang, PhD, Yuhua Li, MD PhD

Blood (2018) 132 (Supplement 1): 2696.

https://doi.org/10.1182/blood-2018-99-118928

Published: 2018

Journal Articles

Combination of CD19 and CD70 Specific Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival in Relapsed and Refractory Primary Central Nervous System Diffuse Large B Cell Lymphoma

Sanfang Tu, MD PhD, Rui Huang, MD PhD, Xuan Zhou, MD, Yanjie He, MD PhD, Zhao Liang, MD PhD, Lei Wang, MD PhD, Lung-Ji Chang, PhD, Yuhua Li, MD PhD

Blood (2018) 132 (Supplement 1): 5389.

https://doi.org/10.1182/blood-2018-99-117694

Published: 2018

Journal Articles

Myc Regulates the Development and Anti-Tumor Immunity of Natural Killer Cells

Yuting Tang, MD PhD, Xiaomei Yan, MD PhD, Di Zhan, PhD, Lijun Wen, MS, Rui Huang, MD PhD, Yue Zhang, MD PhD, Yoshihiro Hayashi, MD PhD, Qianfei Wang, PhD, Jianfeng Zhou, MD PhD, Gang Huang, PhD

Blood (2018) 132 (Supplement 1): 1113.

https://doi.org/10.1182/blood-2018-99-114180

Published: 2018

Journal Articles

Phase I/II Trial of Multi-Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Lung-Ji Chang, PhD, Yuhua Li, MD& PhD, Sanfang Tu, MD& PhD, Xun Lai, MD, Rui Huang, MD& PhD, Shih-Ting Tsao, MSc, Yu-Chen Liu, MSc, Rui Zhang, MSc, Lan Deng, MDPhD, Xuan Zhou, MD, Hongyu Zhang, PhD MD, Wenli Zhang, MD, Yuchen Li, MSc

Blood (2018) 132 (Supplement 1): 225.

https://doi.org/10.1182/blood-2018-99-114396

Published: 2018

Journal Articles

Essential Role of c-MYC for Natural Killer Cell Development, Proliferation and Anti-Tumor Activity

Yuting Tang, MD, Xiaomei Yan, Rui Huang, MD PhD, Yoshihiro Hayashi, MD PhD, Yue Zhang, Wang Qianfei, PhD, Jianfeng Zhou, MD PhD, Gang Huang, PhD

Blood (2017) 130 (Supplement 1): 786.

https://doi.org/10.1182/blood.V130.Suppl_1.786.786

Published: 2017

Journal Articles

Monotcytes/Macrophages Are Involved in Erythrocytosis Caused By Both EPO-Dependent and -Independent Activation of EPOR

Asumi Yokota, PhD, Yoshihiro Hayashi, MD PhD, Jieyu Wang, MD PhD, Rui Huang, MD PhD, Xiaomei Yan, Yue Zhang, MD PhD, Gang Huang, PhD

Blood (2017) 130 (Supplement 1): 449.

https://doi.org/10.1182/blood.V130.Suppl_1.449.449

Published: 2017

NARROW

Addition of Daclizumab to Standard Graft-Versus-Host Disease Prophylaxis in Patients with Thalassemia Major Undergoing Transplantation from Related Haploidentical Donor and Unrelated Donor Hematopoietic Stem-Cell Transplantation: A Single-Center Retrospective Analysis from China

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy with Dual Targeting of CD19 and CD70 to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Trial

Venetoclax Combined with HMA Versus CAG Based Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis

Dendritic Cell Vaccines Extend CD19 CAR-T Cell Persistence and Improve the Outcomes in Refractory/Relapsed Adult B-ALL

Venetoclax Plus Azacitadine for Middle Aged and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD22 to Treat Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults

Linperlisib in Conjunction with Gemcitabine and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Multicenter, Single-Arm Phase Ib/II Study

A Phase Ib Study of Linperlisib Monotherapy in Patients with Relapsed or Refractory B-Cell Malignancies

Letermovir Prophylaxis for Cytomegalovirus Reactivation in β Thalassemia Major Children after Hematopoietic Cell Transplantation

Clinical Characteristics and Prognosis of Acute Myeloid Leukemia Patients with Protein Tyrosine Phosphatase Non-Receptor Type 11 Gene Mutation

Single-Arm Phase 1b/2 Trial of the PI3Kδ Inhibitor Linperlisib Combining with Gemox in Relapsed and/or Refractory Diffuse Large B Cell Lymphoma

Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

A Novel Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD123 to Treat Relapsed Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Therapy of 4s Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival with No Severe CRS or Cres in Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia

Combination of CD19 and CD70 Specific Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival in Relapsed and Refractory Primary Central Nervous System Diffuse Large B Cell Lymphoma

Myc Regulates the Development and Anti-Tumor Immunity of Natural Killer Cells

Phase I/II Trial of Multi-Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Essential Role of c-MYC for Natural Killer Cell Development, Proliferation and Anti-Tumor Activity

Monotcytes/Macrophages Are Involved in Erythrocytosis Caused By Both EPO-Dependent and -Independent Activation of EPOR

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only